We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Morphosys (MOR) NPV

Sell:€67.60 Buy:€67.85 Change: €0.15 (0.22%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:€67.60
Buy:€67.85
Change: €0.15 (0.22%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:€67.60
Buy:€67.85
Change: €0.15 (0.22%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Contact details

Address:
Semmelweisstr. 7
PLANEGG
82152
Germany
Telephone:
+49 (89) 899270
Website:
https://www.morphosys.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MOR
ISIN:
DE0006632003
Market cap:
€2.56 billion
Shares in issue:
37.66 million
Sector:
Biotechnology
Exchange:
Frankfurt Stock Exchange
Country:
Germany
Currency:
Euro
Indices:
n/a

Key personnel

  • Marc Cluzel
    Independent Chairman of the Supervisory Board
  • Jean-Paul Kress
    Chairman of the Management Board, Chief Executive Officer
  • George Golumbeski
    Independent Deputy Chairman Member of the Supervisory Board
  • Lucinda Crabtree
    Chief Financial Officer, Member of the Executive Committee
  • Thomas Biegi
    Senior Vice President, Head of Corporate Affairs, Member of the Executive Committee
  • Luisa Ciccarelli
    Senior Vice President - Global Head of Technical Operations, Member of the Executive Committee
  • Tim Demuth
    Member of the Executive Committee, Chief Research and Development Officer
  • Joe Horvat
    General Manager - US, Member of the Executive Committee
  • Barbara Krebs-pohl
    Member of the Executive Committee, Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.